ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2932 participants.
Also called NCT06611319
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 2,932 participants
- Sponsor
- Prof. Stavros Konstantinides, MD
- Registry
-
NCT06611319 -
2023-507490-18-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria, Germany
- Registry status
- Recruiting
Technical summary
Registry record NCT06611319. Randomized; quadruple masking; primary purpose prevention. Start 2024-11-26 (actual); primary completion 2027-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
- Acronym
- ENABLE-Hip
- Condition
- Hip Arthroplasty, Total
- Condition
- Prevention of Venous Thromboembolism
- Intervention (Drug)
- Prevention of Venous Thromboembolism
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Prof. Stavros Konstantinides, MD
Record details
- Record id
cardio:ct-nct06611319- Content hash
c3bd036e68713be9fd73cfd17ba4178d2599dad23a3be9f3345a4eedb0de70a7